

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7022

Title: 4-AMINOSALICYLIC ACID AND ITS COLON- SPECIFIC PRODRUGS FOR INFLAMMATORY BOWEL DISEASE: PROMISING BUT UNEXPLORED ENTITIES

Reviewer code: 00037649

Science editor: Wen, Ling-Ling

Date sent for review: 2013-11-02 19:41

Date reviewed: 2013-11-16 07:05

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a well-written and comprehensive review of the literature covering the utility of 4-ASA, a positional isomer of 5-ASA, in the treatment of experimental and clinical ulcerative colitis. 1. Although the language and style are very good, the manuscript needs to be carefully edited for punctuation. 2. Change "suppliments" to "supplements" in the last line on page 4. 3. Ensure that the reader can discriminate between the effects of unformulated 4-ASA and formulated (pro-drug) forms of the compound throughout the manuscript, but especially in the sections on pharmacokinetics, interactions, and adverse effects. 4. In "Dose" section on page 9, ensure that pediatric dose is described as mg/kg/day and not as mg, which is inaccurate. Otherwise, the comparison with the adult dose is misleading. Add that this dose is intended for children over 6 years of age. 5. Begin the sections "Interactions" and "Pregnancy" on page 9 with "4-ASA" rather than "It". 6. In section "Colon-specific prodrugs of 4-ASA" on page 10, change "inexpensive option for 5-ASA" to "inexpensive alternative to 5-ASA" 7. In the same section, expand upon the term "polymers" to make it more understandable for the reader. 8. The last sentence on page 12 beginning with "Keeping this fact in view..." is too long and confusing. Try to break it up. 9. Although the way that the compounds are labeled is commonplace for journal dealing with chemistry and medicinal chemistry, they may need to be numbered as figures with legends, depending on the WJG formatting requirements.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7022

Title: 4-AMINOSALICYLIC ACID AND ITS COLON- SPECIFIC PRODRUGS FOR INFLAMMATORY BOWEL DISEASE: PROMISING BUT UNEXPLORED ENTITIES

Reviewer code: 02462155

Science editor: Wen, Ling-Ling

Date sent for review: 2013-11-02 19:41

Date reviewed: 2013-11-18 01:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Dear author, In my opinion this is an interesting manuscript due to all modifications of a drug as 4-ASA would be welcome because improve the quality of the molecule. Despite the appeared new biological therapies such as Infliximab or Adalmumab, other alternatives as 4-ASA must be explored and this review allow to set its prodrugs in the heart of the problem. It is necessary minor language polishing.